Overview

The purpose of this study is to measure the change in dizziness, as measured by change in Dizziness Handicap Inventory (DHI) score, following a 4-week treatment period with aurical transcutaneous vagus nerve stimulation (aTVNS).

Eligibility

Inclusion Criteria:

• Age 18-75, PPPD diagnosis per ICVD.
• Persistent dizziness ≥3 months and at least 1 dizziness exacerbation/day during 2-week run-in.
• On stable medications/therapy for ≥4 weeks prior to baseline (if any).

Exclusion Criteria:

• Uncompensated peripheral/central vestibular deficit, sensory-afferent or cerebellar ataxia.
• Cardiac disease (coronary disease, unstable arrhythmia), recurrent syncope (\>1 in past 12 months).
• Neck surgery, vagotomy, or any condition interfering with vagal stimulation.
• Pregnancy.